Grant Olsen, MD
Internal Medicine · Seymour, INNPI 1750590550
Payments from drug & device makers
Across 399 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$892
- GSK$868
- AbbVie$752
- AstraZeneca$735
- Novartis$672
- Novo Nordisk$569
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,429100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 63 | $892 |
| GSK | 55 | $868 |
| AbbVie | 45 | $752 |
| AstraZeneca | 29 | $735 |
| Novartis | 36 | $672 |
| Novo Nordisk | 34 | $569 |
| Jazz Pharmaceuticals Inc. | 14 | $483 |
| Bayer | 22 | $410 |
| Merck | 22 | $354 |
| Pfizer | 15 | $252 |
| Boehringer Ingelheim | 5 | $165 |
| Otsuka America Pharmaceutical, Inc. | 9 | $157 |
| Amgen | 7 | $118 |
| Echosens North America, Inc. | 2 | $106 |
| Madrigal Pharmaceuticals | 3 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $97 |
| Boston Scientific | 1 | $91 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Monaghan Medical Corporation | 1 | $55 |
| Abbott | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Lundbeck LLC | 2 | $43 |
| Astellas Pharma US Inc | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Exact Sciences | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| La Jolla Pharmaceutical Company | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Grifols USA, LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $16 |
| Vertex | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,453 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $173,744 |
| MounjaroTirzepatide | 114 | $127,578 |
| JardianceEmpagliflozin | 89 | $117,855 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $104,220 |
| OzempicSemaglutide | 82 | $95,226 |
| RybelsusSemaglutide | 50 | $84,844 |
| EntrestoSacubitril/Valsartan | 38 | $51,076 |
| FarxigaDapagliflozin Propanediol | 29 | $36,124 |
| LinzessLinaclotide | 15 | $20,595 |
| RexultiBrexpiprazole | 12 | $20,442 |
| TrulicityDulaglutide | 15 | $20,390 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $16,134 |
| CreonLipase/Protease/Amylase | 13 | $15,687 |
| WegovySemaglutide | 11 | $15,306 |
| MyrbetriqMirabegron | 17 | $14,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $569 | $195,376143 claims |
| PfizerEliquis, Premarin | $252 | $178,351140 claims |
| Lilly USA, LLCMounjaro, Trulicity | $892 | $147,967129 claims |
| Boehringer IngelheimJardiance, Tradjenta | $165 | $128,884101 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $868 | $114,815111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $735 | $52,25741 claims |
| NovartisEntresto | $672 | $51,07638 claims |
| AbbVieLinzess, Creon | $752 | $36,28228 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $157 | $20,44212 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $14,53017 claims |
| Esperion Therapeutics, Inc.Nexletol | $17 | $8,10518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Seymour
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.